Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

Share Price is delayed by 15 minutes
Get Live Data
0.18    -0.0165 (-8.92%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £4.40m
NFX Live PriceLast checked at - London Stock Exchange

Intraday Nuformix Share Chart

Half-year Report

13 Oct 2017 07:00

RNS Number : 5001T
Levrett PLC
13 October 2017
Β 

Β 

Levrett Plc

("Levrett" or the "Company")

Β 

Interim Results

for the period ended 30 September 2017

Β 

Levrett, a company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its interim results for the period ended 30 September 2017.

For further information please contact:

Levrett plc

John Lidgey - Chairman

Β 

+44 (0)20 7183 4342

Β 

Whitman Howard Limited

Financial Advisor to Levrett

Nick Lovering

Β 

+44 (0)20 7659 1234

Β 

Gable Communications Ltd

John Bick

Β 

+44 (0)20 7193 7463

Β 

levrett@gablecommunications.com

Β 

Β 

CHAIRMAN'S STATEMENT

FOR THE PERIOD ENDED 30 September 2017

Β 

Introduction

Β 

These are the results for Levrett Plc for the interim period ended 30 September 2017.

Β 

The company was incorporated on 10 June 2015 and was admitted to the Official List of the UK Listing Authority on 17 December 2015.

Β 

Financial review

Β 

In the six months to 30 September 2017, the Company recorded a loss for the period of Β£77,504 (a loss per share of 0.08 pence). This includes certain fees in relation to the identification of Nuformix Limited as a possible acquisition target, due diligence and advisory fees related to the transaction.

Β 

F J Lidgey

Β 

Chairman

Β 

13 October 2017

LEVRETT PLC

Β 

INTERIM STATEMENT OF COMPREHENSIVE INCOME

FOR THE PERIOD ENDED 30 September 2017

Β 

Β 

Β 

Unaudited

Unaudited

Audited

period ended

period ended

year ended

30 September 2017

30 September 2016

31 March

Β 2017

Β£

Β£

Β£

Revenue

-

-

-

Β 

Β 

Administrative expenses

Β 

Β 

(77,504)

Β 

Β 

(510,957)

Β 

Β 

(685,057)

Β 

LOSS BEFORE TAX

Β 

Β 

Β 

(77,504)

Β 

(510,957)

Β 

(685,057)

Tax

-

-

-

LOSS FOR THE PERIOD

(77,504)

(510,957)

(685,057)

Other comprehensive income/(expense)

-

-

-

TOTAL COMPREHENSIVE EXPENSE

FOR THE PERIOD

Β 

(77,504)

Β 

(510,957)

Β 

(685,057)

Β 

Loss before tax and total comprehensive expense for the period are all attributable to the equity shareholders of the company.

Loss per share

Basic and diluted (pence)

(0.08) p

(0.53) p

(0.72) p

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

LEVRETT PLC

Β 

INTERIM STATEMENT OF FINANCIAL POSITION

FOR THE PERIOD ENDED 30 September 2017

Β 

Β 

Unaudited

Unaudited

Audited

30 September

30 September

31 March

2017

2016

2017

Notes

Β£

Β£

Β£

ASSETS

Current assets

Β 

Trade and other receivables

142,556

35,310

13,727

Cash and cash equivalents

Β 

699

Β 

111,358

Β 

5,895

Β 

143,255

146,668

19,622

TOTAL ASSETS

143,255

146,668

19,622

EQUITY AND LIABILITIES

Equity

Share capital

3

95,750

95,750

95,750

Share premium account

737,440

734,315

737,440

Share Option Reserve

22,695

22,695

22,695

Retained earnings

(1,112,981)

(861,376)

(1,035,477)

Total equity attributable to equity holders of the parent

(257,096)

(8,616)

(179,592)

Current liabilities

Trade and other payables

400,351

155,284

199,214

TOTAL LIABILITIES

400,351

155,284

199,214

TOTAL EQUITY AND LIABILITIES

143,255

146,668

19,622

Β 

LEVRETT PLC

Β 

INTERIM STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 30 September 2017

Β 

Β 

Share

Share

Premium

Share Option

Retained

capital

account

Reserve

earnings

Total

Β£

Β£

Β£

Β£

Β£

On Incorporation

-

-

-

-

-

Total comprehensive expense to date

Β 

-

Β 

-

Β 

-

Β 

(861,376)

Β 

(861,376)

Shares issued

95,750

Β 734,315

22,695

-

852,760

Unaudited at 30 September 2016

95,750

734,315

22,695

(861,376)

(8,616)

Total comprehensive expense to 31 March 2017

Β 

-

Β 

-

Β 

-

Β 

(174,101)

Β 

(174,101)

Grant of share options

-

3,125

-

-

3,125

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Audited at 31 March 2017

95,750

737,440

22,695

(1,035,477)

(179,592)

Total comprehensive expense for period

Β 

-

Β 

-

Β 

-

Β 

(77,504)

Β 

(77,504)

Shares issued

-

-

-

-

-

Unaudited at 30 September 2017

95,750

737,440

22,695

(1,112,981)

(257,096)

Β 

All equity is attributable to equity shareholders of the company.

Β 

Share premium

Β 

Represents amounts subscribed for share capital in excess of its nominal value, net of directly attributable issue costs.

Β 

LEVRETT PLC

Β 

INTERIM STATEMENT OF CASH FLOWS

FOR THE PERIOD ENDED 30 September 2017

Β 

Β 

Β 

Unaudited

Unaudited

Audited

period ended

period ended

Year ended

30 September 2017

30 September 2016

31 March 2017

Β 

Β£

Β£

Β£

Operating activities

Loss before tax

(77,504)

(510,957)

(685,057)

Β 

Changes in working capital:

Share Issue, option of warrants

-

-

3,125

(Increase)/ Decrease in trade and other receivables

(128,829)

7,268

28,851

Increase in trade and other payables

201,137

112,834

156,763

Net cash used in operating activities

(5,196)

(390,855)

(496,318)

Financing activities

Share issue

-

-

-

Net cash generated from financing activities

(5,196)

(390,855)

(496,318)

Taxation

-

-

-

Net decrease in cash and cash equivalents

(5,196)

(390,855)

(496,318)

Cash and cash equivalents at the start of the period

5,895

502,213

502,213

Cash and cash equivalents at the end of the period

699

111,358

5,895

LEVRETT PLC

Β 

NOTES TO THE INTERIM FINANCIAL INFORMATION

FOR THE PERIOD ENDED 30 September 2017

Β 

Β 

1 General information

Β 

Levrett Plc is a publicly listed company incorporated and domiciled in England. The address of its registered office is Suite 31, 2nd Floor, 107 Cheapside, London. EC2V 6DN.

Β 

The Company is listed on the Official List.

This interim financial information was approved for issue on 13 October 2017.

Β 

2 Accounting policies

Β 

2.1 Basis of preparation

The interim financial information comprises the Statements of Financial Position at 30 September 2017, the Statements of Comprehensive Income, Changes in Equity and Cash Flows for the period ended 30 September 2017 and the related notes of Levrett Plc, (hereinafter referred to as "the interim financial information").

Β 

The interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting' as adopted by the European Union. In preparing this information, management have used the accounting policies set by the Company. The auditors' report on the full statutory accounts for the year ended 31 March 2017 included an Emphasis of Matter paragraph with regards to going concern. The accounts for the year ended 31 March 2017 have been filed with the Registrar of Companies.

Β 

This interim financial information does not constitute a set of statutory accounts under the requirements of the Companies Act 2006 and is neither audited nor reviewed.

Β 

This document (the Interim Statement 2017) will be published on the company's website and will be publicly available from the London Stock Exchange regulatory publications. The maintenance and integrity of the Levrett Plc website is the responsibility of the directors. Legislation in the UK governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.

Β 

2.2 Going concern

These financial statements have been prepared on the going concern basis based on the current cash flow projections for the following twelve months. In particular, the directors have assumed that the acquisition of Nuformix Limited and the placing of ordinary shares will be approved by the Company's shareholders on 13 October 2017.

Β 

LEVRETT PLC

Β 

NOTES TO THE INTERIM FINANCIAL INFORMATION

FOR THE PERIOD ENDED 30 September 2017

Β 

Β 

3

Share capital

Unaudited

Unaudited

Audited

Β 

period ended

period ended

year ended

Β 

30 September

2017

30 September

2016

31 March

2017

Β 

Β£

Β£

Β£

Β 

Issued and fully paid

Β 

95,750,000 Ordinary shares issued of Β£0.001 each

95,750

95,750

Β 

95,750

95,750

95,750

95,750

Β 

On Admission to the Official List, 45,750,000 of the above issued share capital was placed at a price of Β£0.02 per share with the premium (net of the issue costs) being shown in the share premium account.

Β 

4

Dividends paid and proposed

Equity dividends on ordinary shares:

Β 

No interim dividend was paid or is proposed for the period ended 30 September 2017.

Β 

5

Loss per share

Β 

The calculations of loss per share are based on the following results and number of shares:

Β 

Unaudited

Unaudited

Audited

Β 

period ended

period ended

year ended

Β 

30 September 2017

30 September 2016

31 March

Β 2017

Β 

Β£

Β£

Β£

Β 

Β 

Loss for the financial period

(77,504)

(510,957)

(685,057)

Β 

Β 

Weighted average number of shares for diluted loss per share

95,750,000

Β 

Β 

95,750,000

95,750,000

Β 

Β 

Β 

At 30 September 2017, the number of ordinary shares in issue was 95,750,000.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

LEVRETT PLC

Β 

DIRECTORS AND OFFICERS

Β 

Β 

Directors

P D Hughes

F J Lidgey

A H Reeves

Secretary

St James Corporate Services Limited

Company Number

09632100

Registered office

Suite 31

2nd Floor, 107 Cheapside

London

EC2V 6DN

www.levrett.com

Broker & Corporate Broker

Whitman Howard Limited

1st Floor, Connaught House

1-3 Mount Street

London

W1K 3NB

Β 

Β 

Auditors

Β 

Β 

haysmacintyre

26 Red Lion Square

London

WC1R 4AG

Solicitors

Shakespeare Martineau LLP

One America Square

Crosswall

London

EC3N 2SG

Registrars

Capita Registrars Limited

The Registry

34 Beckenham Road

Beckenham

Kent

BR3 4TU

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR MMMMGMZGGNZZ
Date   Source Headline
25th Oct 20199:00 amRNSPrice Monitoring Extension
20th Sep 20192:05 pmRNSSecond Price Monitoring Extn
20th Sep 20192:00 pmRNSPrice Monitoring Extension
10th Sep 20194:49 pmRNSAGM Results
10th Sep 20197:00 amRNSDirectorate Change
9th Sep 20197:00 amRNSEbers Cannabinoid Collaboration Update
6th Sep 20197:30 amRNSAppointment of Dr Muhunthan Thillai
4th Sep 20197:30 amRNSHolding(s) in Company
1st Aug 20199:30 amRNSAnnual Financial Report
29th Jul 20197:00 amRNSHolding(s) in Company
18th Jul 20197:00 amRNSFinal Results
7th Jun 20197:00 amRNSHolding(s) in Company
6th Jun 20197:00 amRNSHolding(s) in Company
30th May 201911:05 amRNSSecond Price Monitoring Extn
30th May 201911:00 amRNSPrice Monitoring Extension
30th May 20197:01 amRNSPositive Results for NXP001 Clinical Trial
28th May 20197:00 amRNSHolding(s) in Company - Amendment
24th May 20197:30 amRNSHolding(s) in Company
24th May 20197:00 amRNSLoan Conversion
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
15th May 20194:40 pmRNSSecond Price Monitoring Extn
15th May 20194:35 pmRNSPrice Monitoring Extension
15th May 20197:00 amRNSNuformix Achieves 2nd NXP001 Development Milestone
10th May 20199:00 amRNSPrice Monitoring Extension
8th May 20197:30 amRNSHolding(s) in Company
9th Apr 20197:00 amRNSStrategic Cannabinoid Agreement
5th Apr 20197:00 amRNSNotification Major Share Interests
22nd Mar 20197:00 amRNSNuformix Commences NXP001 Clinical Trial
27th Feb 20197:00 amRNSMHRA approval for NXP001
20th Feb 20196:16 pmRNSHolding(s) in Company
20th Dec 20187:00 amRNSUnaudited Half Year Results
3rd Dec 20187:00 amRNSReports Results from Novel IPF Pre-Clinical Trial
27th Nov 20187:00 amRNSExpansion of NXP001 Agreement & Milestone Payment
28th Sep 201810:09 amRNSDirector/PDMR Shareholding
28th Sep 20187:00 amRNSAdditional New NXP002 Patent Filing
19th Sep 20182:33 pmRNSResult of AGM
14th Sep 20187:00 amRNSNXP001 Pre-Clinical Milestone Achieved
28th Aug 201812:55 pmRNSConvertible Loan Amendment
16th Aug 20187:00 amRNSAnnual Report and Notice of AGM
26th Jul 20182:00 pmRNSFinal Results
9th Jul 20189:33 amRNSHolding(s) in Company
2nd Jul 20187:00 amRNSOperational Update
26th Jun 20188:00 amRNSCollaboration with SGSC
11th May 20187:00 amRNSDr Chris Blackwell Appointed NED
24th Apr 201811:54 amRNSHolding(s) in Company
11th Apr 20184:41 pmRNSStmnt re Share Price Movement
2nd Mar 20181:30 pmRNSUpdate re: Broker
27th Feb 20189:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.